<!DOCTYPE html>
<html lang="en">

<head>
   <meta charset="UTF-8">
   <meta http-equiv="X-UA-Compatible" content="IE=edge">
   <meta name="viewport" content="width=device-width, initial-scale=1.0">
   <title>Document</title>
   <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.1.2/css/all.min.css">
  <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;600&display=swap" rel="stylesheet">
   <link href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/4.6.0/css/bootstrap.min.css" rel="stylesheet">
   <link href="https://cdnjs.cloudflare.com/ajax/libs/OwlCarousel2/2.3.4/assets/owl.carousel.min.css" rel="stylesheet">
   <link rel="stylesheet" href="style2.css">
</head>
<style>
   .content {
      display: flex;
      justify-content: center;
      width: 100%;
      align-items: center;
      flex-wrap: wrap;
      margin-top: 1rem;
   }

   .contnetimg {
      width: 28%;
      border: 1px solid black;
      min-width: 300px;

   }

   .contentparas {
      font-family: 'Lucida Sans', 'Lucida Sans Regular', 'Lucida Grande', 'Lucida Sans Unicode', Geneva, Verdana, sans-serif;
      justify-content: baseline;
      width: 90%;
      margin-left: 1rem
   }

   .heads {
      font-size: 23px;
      margin-top: 2rem;
      flex-wrap: wrap;
      justify-content: center;
      text-align: center;
      align-items: center;
      width: 80%;

   }

   .para {
      margin-top: 1rem;
      font-family: sans-serif;
      font-size: 18px;
      font-weight: 600;
      width: 100%;
      flex-wrap: wrap;
   }

   @media (max-width:400px) {
      .para {
         width: 100%;
      }

      .heads {
         justify-content: center;
         width: 90%;
         text-align: center;
         align-items: center;
         flex-wrap: wrap;
      }
   }

   .head3 {
      justify-content: center;
      display: flex;
      text-align: center;
      width: 100%;
      align-items: center;
      font-size: 23px;
      margin-top: 2rem;
      flex-wrap: wrap;
      justify-content: center;
      text-align: center;
      align-items: center;


   }
</style>

<body>
   <div class="logo">
      <a href="#"><span style="color: black;"> OBGYNI </span><span style="color:red ;"> NSIGHT </span></a>
   </div>
   <header class="header">
      <div class="container">
          <div class="row align-items-center justify-content-between">
              
              <button type="button" class="nav-toggler">
               <span style="margin-top: -0.5rem;"><i class="fa-solid fa-bars"></i></span>
            </button>
              <nav class="nav">
                 <ul>
                    <li><a href="index.html" class="active">Home</a></li>
                    <li><a href="webinar.html">Webinars</a></li>
                    <li><a href="educationvido.html">Educational video</a></li>
                    <li><a href="#c">Conditions</a></li>
                    <li><a href="#">Contact</a></li>
                 
                 </ul>
              </nav>
          </div>
      </div>
   </header>
   
   
  

   <div class="condion">
      <h1>ENDOMETRIOSIS</h1>
   </div>


   <div class="head3">
      <p>
         <b>
            Treatment of Thoracic Endometriosis Syndrome: A Meta-Analysis and Review

            :</b>
      </p>
   </div>

   <div class="content">
      <div class="contnetimg">
         <img src="endo2.jpg">

      </div>


      <div class="contentparas">


         <div class="para">
            The aim of the study was to analyze the different approaches to generate an ideal diagnosis-treatment
            algorithm that can be shared by both thoracic surgeons and gynecologists. Up to 80% of women with Thoracic
            endometriosis syndrome present
            with concomitant pelvic endometriosis.
            Twenty-five studies including a total of 732 patients were eligible. Almost all of the patients underwent
            radiologic pelvis investigation (96%; confidence interval [CI], (87%-100%). Postoperative hormone therapy
            was heterogeneous with a pooled prevalence of 61% (95% CI, 33%-86%). TES should be managed jointly by
            thoracic surgeons and gynecologists.

         </div>
      </div>




      <div class="heads">

         <b>
            Analysis of the clinical efficacy of leuprolide acetate in the treatment of obese patients with
            endometriosis and its role on the expression of MIF gene
      </div>
      <div class="content">
         <div class="contnetimg">
            <img src="endo4.jfif" alt="">

         </div>


         <div class="contentparas">


            <div class="para">
               <p>Endometriosis is an invasive but benign disease of women that develops in endometrial glands outside
                  the endometrium and uterine muscle. Obesity and an increase in BMI are potential adverse effects of
                  this medication that some patients are concerned about. In this six-month trial, leuprolide acetate's
                  effects on overweight individuals with BMIs more than 30 were compared to those of non-overweight
                  patients with BMIs less than 30. Additionally, the impact of this medication was assessed on the
                  expression of the MIF gene, a gene that plays a significant role in obesity. The patients were split
                  into two groups: the first group included 38 patients with BMIs below 30 and the second group included
                  37 patients with BMIs above 30. According to the findings, the medication
               </p>
            </div>
         </div>



         <div class="heads">

            <b>
               What Voice-Related Metrics Change With Menopause? A Systematic Review and Meta-Analysis Study
            </b>
         </div>
         <div class="content">
            <div class="contnetimg">
               <img src="edno1.webp" alt="">

            </div>


            <div class="contentparas">


               <div class="para">
                  <p>A large number of studies have noted voice issues related to menopause. However, it is unclear how
                     much menopausal symptoms are reflected in voice measurements. A comprehensive review and
                     meta-analysis was carried out to identify voice-related metrics that change with menoapause.
                     Meta-analyses assessed the effects of menopause on 6 voice metrics. Voice fundamental frequency and
                     sustained vowel /a/ were found to be 0.94 and 1.18 semitones lower in post- as compared to
                     pre-menopausal women. No significant differences were found for jitter, shimmer or
                     noise-to-harmonics ratio.decreased dysmenorrhea, dyspareunia, and persistent pelvic discomfort.
                     Leuprolide acetate was administered intramuscularly to both groups at a dose of 3.75 mg monthly for
                     a total of six months.
                     In general, it was discovered that this medicine makes obese individuals acquire more weight and
                     raises their chance of developing disorders linked to obesity. Therefore, it is advised that
                     patients with endometriosis who are obese utilise this medication with care.

                  </p>
               </div>
            </div>

            <div class="heads">

               <b>

                  Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated
                  pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2)
               </b>
            </div>
            <div class="content">
               <div class="contnetimg">
                  <img src="meno6.jpg" alt="">

               </div>


               <div class="contentparas">


                  <div class="para">
                     <p>dysmenorrhoea Numerical Rating Scale (NRS) score of 4·0 or higher on two or more days and a mean
                        non-menstrual pelvic pain NRS score of 2·5 or higher. Eligible patients could enrol in an
                        ongoing 80-week open-label extension study.
                        Once-daily relugolix combination therapy significantly improved endometriosis-associated pain
                        and was well tolerated. This oral therapy has the potential to address the unmet clinical need
                        for long-term medical treatment for endometriosis, reducing the need for opioid use or repeated
                        surgical treatment.

                     </p>
                  </div>
               </div>

               <div class="heads">

                  <b>



                     <p></p> Study outcome and Summary points of Systematic review and Meta-analysis on Dienogest


                  </b>
               </div>
               <div class="content">
                  <div class="contnetimg">
                     <img src="endo8.png" alt="">

                  </div>


                  <div class="contentparas">


                     <div class="para">
                        <p>Dienogest is superior to gonadotropin-releasing hormone analogues(GnRH-a)in relieving pain.
                           In comparison to dienogest, GnRH-a more likely to lead to the loss of bone mineral density
                           and associated with a higher incidence of headaches and hot flushes. Dienogest shows better
                           pain-relief in endometriosis patients, due to its high efficacy and tolerability. Dienogest
                           suppresses the growth of endometrioid tissue, exerts anti-inflammatory, antiproliferative,
                           and antiangiogenic effects. Dienogest shows good effectiveness and a favorable safety profile
                           in long-term clinical application and follow-up studies. Study quoted that the incidence of
                           hot flushes are greater in women treated with GnRH-a than in women treated with dienogest.
                           Meta-analysis findings indicate that dienogest should be the first-line treatment for
                           endometriosis. The patients’ dependence on supportive analgesics decreases in dienogest
                           treatment. Meta-analysis evaluated the efficacy and safety of dienogestforthe treatment of
                           endometriosis. The results showed that dienogest is superior to placebo andGnRH-a in terms of
                           pain relief and is better tolerated than GnRH-a. This demonstrates that dienogest is the best
                           medication for endometriosis patients seeking pain relief
                        </p>
                     </div>
                  </div>





               </div>
               <section>
                  <footer class="footer" ">           
                     <div class="container">
                     <div class="row">
                        <div class="footer-col">
                           <h4>company</h4>
                           <ul>
                              <li><a href="#">about us</a></li>
                              <li><a href="#">our services</a></li>
                              <li><a href="webinar.html">our Webinars</a></li>
                              <li><a href="educationvido.html">Educational videos</a></li>
                           </ul>
                        </div>
                        <div class="footer-col">
                           <h4>get help</h4>
                           <ul>
                              <li><a href="#">FAQ</a></li>
              <li><a href="#">Contact us</a></li>
                
                           </ul>
                        </div>
                        <div class="footer-col">
                           <h4>online shop</h4>
                           <ul>
                              <li><a href="infertility.html">infertility</a></li>
                              <li><a href="pregnancy.html">pregnancy</a></li>
                              <li><a href="prgcomplcation.html">Pregnancy Complication</a></li>
                              <li><a href="menopause.html">menopause</a></li>
                              <li><a href="endromentsr.html">endometriosis</a></li>
                              <li><a href="menstrualdisorder.html">menstrual disorder</a></li>
                           </ul>
                        </div>
                        <div class="footer-col">
                           <h4>follow us</h4>
                           <div class="social-links">
                              <a href="#"><i class="fab fa-facebook-f"></i></a>
                              <a href="#"><i class="fab fa-twitter"></i></a>
                              <a href="#"><i class="fab fa-instagram"></i></a>
                              <a href="#"><i class="fab fa-linkedin-in"></i></a>
                           </div>
                        </div>
                     </div>
                  </div>
              </footer>

</body>
<script>
 

 const navToggler = document.querySelector(".nav-toggler"); 
  navToggler.addEventListener("click", navToggle);
   function navToggle() 
   { navToggler.classList.toggle("active");
    const nav = document.querySelector(".nav");
     nav.classList.toggle("open");
      if(nav.classList.contains("open")){ nav.style.maxHeight = nav.scrollHeight + "px"; }
  else{ nav.removeAttribute("style"); } }
</script>

</html>